Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 14/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 13/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111293 | 0.98 | FEN1 (0.42) | FEN1ALOX5APPTPN5HDAC4HDAC2 | |
| SCHEMBL20111473 | 0.98 | FEN1 (0.42) | FEN1ALOX5APPTPN5HDAC4HDAC2 | |
| SCHEMBL20111695 | 0.97 | FEN1 (0.43) | FEN1ALOX5APPTPN5 | |
| SCHEMBL20111271 | 0.94 | FEN1 (0.35) | FEN1ALOX5AP | |
| SCHEMBL20111543 | 0.87 | ESR2 (0.36) | FEN1ALOX5AP | |
| SCHEMBL20111430 | 0.83 | ALOX5AP (0.30) | FEN1ALOX5AP | |
| SCHEMBL20111508 | 0.83 | ESR2 (0.33) | FEN1ALOX5AP | |
| SCHEMBL20111340 | 0.82 | — | — | |
| SCHEMBL20102511 | 0.81 | FEN1 (0.36) | FEN1ALOX5AP | |
| SCHEMBL20111486 | 0.81 | MEN1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | FEN1 1547/4885ALOX5AP 2002/4885PTPN5 2145/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | FEN1 1547/4885ALOX5AP 2002/4885PTPN5 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.